Overview

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Status:
Active, not recruiting

Trial end date:
2024-04-10

Target enrollment:

Participant gender:

Summary

This is a one stage phase II study with a single arm design. It will be conducted in HER-2 positive breast cancer patients in Nigeria who are chemotherapy/hormonal treatment naive.

Phase:

Phase 2

Details

Lead Sponsor:

University of Chicago

Treatments:

Docetaxel
Hormones
Letrozole
Tamoxifen
Trastuzumab